Plain-English translation of NCT07234942 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer's Disease research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new medication called that is delivered directly into the fluid surrounding your spine to treat early-stage Alzheimer's disease. Researchers want to understand whether this medication is safe, how your body handles it, and whether it affects the disease process. About half of participants will receive the medication and half will receive a placebo (inactive injection), and neither you nor the study doctors will know which group you're in.
Current Alzheimer's treatments help manage symptoms but don't stop the disease from progressing. This trial is exploring whether delivering treatment directly into the spinal fluid might be a more effective way to reach the brain and slow the disease's course in its early stages.
You likely qualify if…
You likely don't qualify if…
You will visit the study site to receive a single injection of either the new medication or placebo into the fluid around your spine. The study team will monitor you closely for safety and side effects, drawing blood samples and performing thinking and memory tests. Your participation involves visits to assess how you're responding to the treatment and to gather information about how your body processes the medication.
AI-generated summary from trial data · Jul 4, 2026 · Not medical advice
Canada
Netherlands
Spain